Researchers developed the Splicing Neo Antigen Finder (SNAF) workflow, integrating deep learning to identify shared immunogenic neoantigens in cancers, offering new targets for cancer immunotherapy, particularly in melanoma and ovarian cancer.
Thermo Fisher cuts 2023 forecast, citing volatile economic conditions
Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. By the numbers Q3 revenue: $10.57 billion